| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Palatin Technologies, Inc.: Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity | 121 | PR Newswire | Phase 2 clinical study expected to begin in mid-calendar year 2024
Topline data expected by calendar year-end 2024
Hosting virtual KOL event "Beyond GLPs" on May 8, 2024
Focus will be on Company's... ► Artikel lesen | |
| 12.04. | Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying | 69 | Benzinga.com | ||
| 08.04. | Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data | 38 | Benzinga.com | ||
| 08.04. | Palatin Technologies, Inc.: Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 | 107 | PR Newswire | Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation
Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P Statistical Significance (P
Rapid Onset of Efficacy... ► Artikel lesen | |
| 14.03. | PALATIN TECHNOLOGIES INC - S-1, General form for registration of securities | 61 | SEC Filings | ||
| 28.02. | Palatin Technologies: Aktie schmiert ab - das steckt dahinter | 1.688 | finanztreff.de | Palatin hat am Mittwochmittag Studienergebnisse zu einem Medikament gegen Augentrockenheit veröffentlicht. Die Aktie schmiert daraufhin ab.Palatin Technologies, ein Unternehmen aus dem biopharmazeutischen... ► Artikel lesen | |
| 28.02. | Pre-market Movers: Bit Brother, Beyond Meat, Oragenics, Palatin Technologies, Integral Ad Science | 705 | AFX News | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.10 A.M. ET).In the Green Bit Brother Limited (BETS) is up over 68%... ► Artikel lesen | |
| 28.02. | Palatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) | 533 | PR Newswire | On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P
Multiple Secondary Symptom Endpoints Met, Statistical Significance (P
On an Intent-to-Treat Analysis... ► Artikel lesen | |
| 15.02. | PALATIN TECHNOLOGIES INC - 8-K, Current Report | 36 | SEC Filings | ||
| 15.02. | Palatin Technologies Inc. Q2 Earnings Summary | 463 | AFX News | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Palatin Technologies Inc. (PTN):Earnings: -$7.84 million in Q2 vs. $2.71 million in the same period last year.
EPS: -$0.56 in Q2... ► Artikel lesen | |
| 15.02. | Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update | 344 | PR Newswire | Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline
PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED)- Topline Data Expected in February
Oral... ► Artikel lesen | |
| 05.02. | Palatin Technologies, Inc.: Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) | 670 | PR Newswire | Top-Line Results Expected in February
CRANBURY, N.J., Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines... ► Artikel lesen | |
| 01.02. | PALATIN TECHNOLOGIES INC - 8-K, Current Report | 42 | SEC Filings | ||
| 30.01. | Palatin Technologies Prices Offering Of $10 Mln Of Shares; Stock Down Over 4% In Pre-Market | 510 | AFX News | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN), a biopharmaceutical company, said on Tuesday that it has inked a deal with institutional investors for the issuance and sale of its 1... ► Artikel lesen | |
| 08.01. | Palatin Technologies, Inc.: Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 | 347 | PR Newswire | Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study
Data Base Lock 2H January 2024
Topline Data Readout Expected Early 1Q Calendar Year 2024
Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical... ► Artikel lesen | |
| 03.01. | Cosette Pharmaceuticals Acquires Vyleesi (Bremelanotide Injection) from Palatin Technologies Inc. | 458 | Business Wire | BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women's health and cardiovascular medicines, has completed... ► Artikel lesen | |
| 29.12.23 | Palatin Technologies, Cellectis among healthcare movers | 57 | Seeking Alpha | ||
| 20.12.23 | Palatin Technologies Completes Sale Of Vyleesi To Cosette Pharma For Up To $171 Mln | 559 | AFX News | WASHINGTON (dpa-AFX) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Wednesday the sale of Vyleesi to US-based speciality pharmaceutical company Cosette Pharmaceuticals... ► Artikel lesen | |
| 18.12.23 | PALATIN TECHNOLOGIES INC - 8-K, Current Report | 17 | SEC Filings | ||
| 04.12.23 | Palatin Technologies files to sell 2.48M shares of common stock for holders | 84 | Seeking Alpha |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 3.788 |
| NEL | 3.679 |
| PALANTIR TECHNOLOGIES | 3.346 |
| TUI | 2.523 |
| BAYER | 2.294 |
| INFINEON | 2.274 |
| SIEMENS ENERGY | 2.100 |
| DEUTSCHE BANK | 1.959 |
| NVIDIA | 1.828 |
| MERCEDES-BENZ | 1.821 |
| DEUTSCHE LUFTHANSA | 1.818 |
| BYD | 1.633 |
| VARTA | 1.549 |
| ALLIANZ | 1.450 |
| RHEINMETALL | 1.393 |
| PLUG POWER | 1.321 |
| AIXTRON SE | 1.295 |
| TESLA | 1.257 |
| RENK GROUP | 1.248 |
| RWE | 1.243 |
| SUPER MICRO COMPUTER | 1.206 |
| COMMERZBANK | 1.198 |
| VOLKSWAGEN | 1.167 |
| BASF | 1.090 |
| TEAMVIEWER | 1.036 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
